Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting

被引:108
作者
Handgretinger, R
Lang, P
Schumm, M
Taylor, G
Neu, S
Koscielnak, E
Niethammer, D
Klingebiel, T
机构
[1] Univ Tubingen, Childrens Hosp, D-72070 Tubingen, Germany
[2] Olgahosp Stuttgart, Stuttgart, Germany
关键词
CD34; isolation; MACS; high-dose chemotherapy;
D O I
10.1038/sj.bmt.1701228
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Peripheral stem cells were mobilized and collected in 26 pediatric patients with malignant diseases. A total of 47 leukaphereses were performed in the 26 patients. The mean number of nucleated cells collected was 4.5 +/- 2.6 x 10(8)/kg and the number of CD34(+) progenitors collected was 6.7 +/- 6.8 x 10(6)/kg. CD34-positive selection was performed using a two-step method of magnetic-activated cell sorting (MACS) in 24 patients or a combination of an immunoaffinity column and MACS in two patients. The purity of the positively selected CD34(+) progenitors was 98.8 +/- 0.7% and the number of isolated CD34(+) cells was 6.5 +/- 5.9 x 10(6)/kg. Thus, the mean recovery of CD34(+) cells was 93 +/- 10%. In 22 of the 26 patients, high-dose chemotherapy was performed with subsequent reinfusion of the highly purified CD34(+) cells. In all 22 patients, a normal hematopoietic reconstitution was seen with a mean time of 12.4 +/- 2.7 days to reach >0.5 x 10(9)/I neutrophils (range 8-19 days). The time to reach independence from platelet transfusion was 31.6 +/- 17.0 days (range 16-78 days). There were no transplant-related deaths. In summary, we have shown that mobilized peripheral CD34(+) progenitors can be highly purified with a good recovery and that reinfusion of these cells after high-dose chemotherapy results in a rapid, complete and sustained engraftment. We conclude that this method can be used for purging in any CD34-negative malignancies and for autologous T and B cell depletion in the treatment of autoimmune diseases with high-dose immunoablative therapy.
引用
收藏
页码:987 / 993
页数:7
相关论文
共 28 条
  • [1] BERENSON RJ, 1991, BLOOD, V77, P1717
  • [2] Brenner M K, 1994, J Hematother, V3, P33, DOI 10.1089/scd.1.1994.3.33
  • [3] GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    BRENNER, MK
    RILL, DR
    MOEN, RC
    KRANCE, RA
    MIRRO, J
    ANDERSON, WF
    IHLE, JN
    [J]. LANCET, 1993, 341 (8837) : 85 - 86
  • [4] BRUGGER W, 1994, BLOOD, V83, P636
  • [5] BURT RK, 1995, BONE MARROW TRANSPL, V16, P1
  • [6] COMPARISON OF PURITY AND ENRICHMENT OF CD34(+) CELLS FROM BONE-MARROW, UMBILICAL-CORD AND PERIPHERAL-BLOOD (PRIMED FOR APHERESIS) USING 5 SEPARATION SYSTEMS
    DEWYNTER, EA
    COUTINHO, LH
    PEI, X
    MARSH, JCW
    HOWS, J
    LUFT, T
    TESTA, NG
    [J]. STEM CELLS, 1995, 13 (05) : 524 - 532
  • [7] GALE RP, 1992, BONE MARROW TRANSPL, V9, P151
  • [8] Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma
    Handgretinger, R
    Greil, J
    Schurmann, U
    Lang, P
    GonzalezRamella, O
    Schmidt, I
    Fuhrer, R
    Niethammer, D
    Klingebiel, T
    [J]. JOURNAL OF HEMATOTHERAPY, 1997, 6 (03): : 235 - 242
  • [9] HANDGRETINGER R, 1992, CANCER RES THER CONT, V3, P43
  • [10] A PHASE-I STUDY OF HUMAN MOUSE CHIMERIC ANTIGANGLIOSIDE GD2 ANTIBODY CH14.18 IN PATIENTS WITH NEUROBLASTOMA
    HANDGRETINGER, R
    ANDERSON, K
    LANG, P
    DOPFER, R
    KLINGEBIEL, T
    SCHRAPPE, M
    REULAND, P
    GILLIES, SD
    REISFELD, RA
    NIETHAMMER, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) : 261 - 267